Non-clear Cell Renal Cell Carcinoma

• CLINICAL_TRIALS research · 2026-04-14
  Clinical Trial Update: Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma [Phase 2]

  This update notes a Phase 2 clinical trial investigating the combination of tivozanib and nivolumab in advanced non-clear cell renal cell ca…

• CLINICAL_TRIALS research · 2026-04-14
  Clinical Trial Update: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors [Phase 1]

  KO-2806 is being studied in Phase 1 trials as a monotherapy and in combination regimens for advanced solid tumors, including HRAS-altered ca…

• CLINICAL_TRIALS research · 2026-04-07
  Clinical Trial Update: A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma [Phase 1, Phase 2]

  A clinical trial update on AK104 plus axitinib in advanced/metastatic special pathological subtypes of renal cell carcinoma (Phase 1/Phase 2…

• CLINICAL_TRIALS research · 2026-03-23
  Clinical Trial Update: Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma [Phase 2]

  Phase 2 trial evaluating the combination of Sullumab and Fruquintinib as postoperative adjuvant therapy for high-risk non-clear cell renal c…

• CLINICAL_TRIALS research · 2026-03-12
  Clinical Trial Update: Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors [Phase 1]

  A Phase 1 study evaluating Zanzalintinib in combination with immuno-oncology agents in patients with various solid tumors; recruitment is on…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2025-07-14
  Clinical Trial Update: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma [Phase 3]

  Phase 3 study evaluating XL092 in combination with nivolumab versus sunitinib in advanced or metastatic non-clear cell renal cell carcinoma;…

• CLINICAL_TRIALS research · 2024-12-19
  Clinical Trial Update: Fruquintinib and SeRplulimab: Opening New Frontiers in Treating Non-clear Cell Renal Cell Carcinoma [Phase 2]

  Phase 2 trial evaluating Fruquintinib plus SeRplulimab for non-clear renal cell carcinoma is currently recruiting.